Hepatic and gastrointestinal disturbances in Egyptian patients infected with coronavirus disease 2019: A multicentre cohort study
Hend Ibrahim Shousha, Shimaa Afify, Rabab Maher, Noha Asem, Eman Fouad, Ehab F Mostafa, Mohammed A Medhat, Amr Abdalazeem, Hazem Elmorsy, Miriam M Aziz, Rateba S Mohammed, Mohamed Ibrahem, Hassan Elgarem, Dalia Omran, Egyptian Mohamed Hassany, Bassem Elsayed, Ahmed Y Abdelaziz, Mohamed El Kassas
World Journal of Gastroenterology, doi:10.3748/wjg.v27.i40.6951
Informed consent statement: All study subjects gave written informed consent before study inclusion.
Author contributions: Shousha HI October 28, 2021 Volume 27 Issue 40
Research motivation Comprehensive researches on hepatic and GI derangements in patients with COVID-19 are still lacking, and they are needed for better understanding of the underlying factors, clinical presentations, and disease outcome
Research objectives We aimed to study the prevalence and severity of liver and GI derangements in Egyptian patients with COVID-19 infection and their relation to disease outcomes.
Research methods This multicentre cohort study was conducted on 547 COVID-19 cases from four quarantine hospitals during the period from April 15, 2020 to July 29, 2020. Clinical, laboratory features, fibrosis-4 (FIB-4) index, COVID-19 severity, and outcomes were recorded. Follow-ups were conducted until discharge or death.
Research results Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were elevated in 26% and 32% of patients while elevations above 3 fold were recorded in 4.91% and 3.73% patients, respectively. Male gender, smoking, hypertension, chronic hepatitis C, and lung involvement were associated with elevated AST or ALT. FIB-4 was significantly higher in patients admitted to the intensive care unit (ICU), those with more severe COVID-19, and non-survivors. The independent variables affecting outcome were supplementary vitamin C intake, lung consolidation, ICU admission, and FIB-4 score > 3.25. GI symptoms were present in 60 (13.98%) patients. They were..
References
Abdalazeem, None
Ahmed Y Abdelaziz, None
Asem, None
Aziz, None
Burton, Fort, Seoane, Hospitalization and Mortality among Black Patients and White Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMsa2011686Chan, Biostatistics 103: qualitative data -tests of independence, Singapore Med J
Chan, Biostatistics 202: logistic regression analysis, Singapore Med J
Ehab, Mostafa, None
Elgarem, None
Elsayed, None
Feng, Zheng, Yan, Rios, Targher et al., COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies, J Clin Transl Hepatol,
doi:10.14218/JCTH.2020.00018Fouad, None
Frater, Zini, Onofrio, Rogers, Chan, Biostatistics 102: quantitative data--parametric & non-parametric tests,
doi:10.1111/ijlh.13229Hassany, None
Ibrahem, None
Kassas, None
Kulkarni, Kumar, Tevethia, Premkumar, Arab et al., Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19, Aliment Pharmacol Ther,
doi:10.1111/apt.15916Kumar, Harne, Mukherjee, Gupta, Masood et al., Transaminitis is an indicator of mortality in patients with COVID-19: A retrospective cohort study, World J Hepatol,
doi:10.4254/wjh.v12.i9.619Li, Regan, Fajnzylber, Coxen, Corry et al., Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19, Hepatol Commun,
doi:10.1002/hep4.1650Liu, Yang, Wang, Zheng, Tang, Liver injury could be associated with severe disease in COVID-19 patients: a meta-analysis, Eur J Gastroenterol Hepatol,
doi:10.1097/MEG.0000000000001953Luo, Zhang, Xu, Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19), Clin Gastroenterol Hepatol,
doi:10.1016/j.cgh.2020.03.043Maher, None
Mohammed A Medhat, None
Musa, Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now?, Arab J Gastroenterol,
doi:10.1016/j.ajg.2020.03.002Nobel, Phipps, Zucker, Lebwohl, Wang et al., Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States, Gastroenterology,
doi:10.1053/j.gastro.2020.04.017Omran, None
Parasa, Desai, Chandrasekar, Patel, Kennedy et al., Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.11335Phipps, Barraza, Lasota, Sobieszczyk, Pereira et al., Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort, Hepatology,
doi:10.1002/hep.31404Ponziani, Zompo, Nesci, Santopaolo, Ianiro et al., Gemelli against COVID-19" group. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients, Aliment Pharmacol Ther,
doi:10.1111/apt.15996Rateba, None
Redd, Zhou, Hathorn, Mccarty, Bazarbashi et al., Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study, Gastroenterology,
doi:10.1053/j.gastro.2020.04.045Rentsch, Kidwai-Khan, Tate, Park, King et al., Covid-19
Sterling, Lissen, Clumeck, Sola, Correa et al., Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology,
doi:10.1002/hep.21178Sterling, Oakes, Gal, Stevens, Dewit et al., The Fibrosis-4 Index Is Associated With Need for Mechanical Ventilation and 30-Day Mortality in Patients Admitted With Coronavirus Disease 2019, J Infect Dis,
doi:10.1093/infdis/jiaa550Wan, Wang, Su, Zhang, Jin et al., Digestive symptoms and liver injury in patients with coronavirus disease 2019 (COVID-19): A systematic review with meta-analysis, JGH Open,
doi:10.1002/jgh3.12428Wang, Qiu, Liu, Wang, Zhao, The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis, Clin Res Hepatol Gastroenterol,
doi:10.1016/j.clinre.2020.04.012Wijarnpreecha, Ungprasert, Panjawatanan, Harnois, Zaver et al., COVID-19 and liver injury: a meta-analysis, Eur J Gastroenterol Hepatol,
doi:10.1097/MEG.0000000000001817Wu, Li, Guo, Yoshida, Mendez-Sanchez et al., Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis, Hepatol Int,
doi:10.1007/s12072-020-10074-6Xing, Dong, Ren, Chen, Zeng et al., Liver Chemistries in Patients with COVID-19 Who Discharged alive or Died: A Meta-analysis, Hepatol Commun,
doi:10.1002/hep4.1585Youssef, Hussein, Attia, Elshazli, Zora et al., COVID-19 and liver dysfunction: A systematic review and meta-analysis of retrospective studies, J Med Virol,
doi:10.1002/jmv.26055Zhong, Xu, Yang, Shen, Wang et al., COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms, Signal Transduct Target Ther,
doi:10.1038/s41392-020-00373-7
